11:00 - 11:05 | Introduction: Nicolaus Kröger
11:05 - 11:25 | BTK, BCL2 inhibitors or PI3K combined with stem cell transplantation for CLL: Johannes Schetelig
11:25 - 11:45 | IMiDs, proteasome-inhibitors and antibodies as part of a transplant package for multiple myeloma: Holger Auner
11:45 - 12:05 | JAK inhibitor before, during and after stem cell transplantation for myelofibrosis: Donal McLornan
12:05 - 12:25 | Hypomethylating agents pre- and post-transplantation for MDS: Marie Robin
12:25 - 12:30 | Conclusion: Nicolaus Kröger
Todos os direitos reservados